Bristol Myers Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?
BRISTOL MYERS has seventy-six approved drugs.
There are thirteen US patents protecting BRISTOL MYERS drugs.
There are five hundred and ninety-six patent family members on BRISTOL MYERS drugs in fifty-one countries and one hundred and forty-four supplementary protection certificates in eighteen countries.
Summary for Bristol Myers
International Patents: | 596 |
US Patents: | 13 |
Tradenames: | 65 |
Ingredients: | 58 |
NDAs: | 76 |
Drug Master File Entries: | 1 |
Drugs and US Patents for Bristol Myers
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers | QUESTRAN LIGHT | cholestyramine | POWDER;ORAL | 019669-001 | Dec 5, 1988 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 9,732,062 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | AB | RX | Yes | No | 7,465,800 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol Myers
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SUSTIVA | efavirenz | CAPSULE;ORAL | 020972-001 | Sep 17, 1998 | 6,639,071*PED | ⤷ Try a Trial |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | 8,404,717 | ⤷ Try a Trial |
Bristol Myers Squibb | ZERIT XR | stavudine | CAPSULE, EXTENDED RELEASE;ORAL | 021453-001 | Dec 31, 2002 | 4,978,655*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
International Patents for Bristol Myers Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2919382 | ⤷ Try a Trial |
Japan | 2009173683 | ⤷ Try a Trial |
Japan | 2017039768 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol Myers Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1169038 | 13C0003 | France | ⤷ Try a Trial | PRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/06/363/001 20061122 |
1380301 | CA 2009 00017 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
2487163 | 1790002-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/15/1025, 2015-07-15 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.